| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0376-8716(99)00127-1 |
| P698 | PubMed publication ID | 10812285 |
| P50 | author | Harriet de Wit | Q37369399 |
| P2093 | author name string | Wachtel SR | |
| P2860 | cites work | Cannabinoid receptor localization in brain | Q24558751 |
| An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing | Q28235579 | ||
| Structure of a cannabinoid receptor and functional expression of the cloned cDNA | Q28240076 | ||
| Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors | Q28292914 | ||
| Molecular characterization of a peripheral receptor for cannabinoids | Q28298338 | ||
| Isolation and structure of a brain constituent that binds to the cannabinoid receptor | Q29547476 | ||
| Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor | Q34358410 | ||
| Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra | Q34421920 | ||
| Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. | Q34602111 | ||
| Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis | Q34631075 | ||
| Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction | Q36482564 | ||
| Assessment of abuse liability of stimulant drugs in humans: a methodological survey | Q36515914 | ||
| Marijuana's interaction with brain reward systems: update 1991. | Q37028121 | ||
| Analgesic Effect of Delta‐9‐Tetrahydrocannabinol | Q39589738 | ||
| Self-administration of Δ9-tetrahydrocannabinol by rats | Q40290487 | ||
| Strain-specific facilitation of dopamine efflux by Δ9-tetrahydrocannabinol in the nucleus accumbens of rat: An in vivo microdialysis study | Q41130886 | ||
| THC does not affect striatal dopamine release: Microdialysis in freely moving rats | Q41141136 | ||
| Naloxone-induced or postwithdrawal abstinence signs in ?9-Tetrahydrocannabinol-Tolerant rats | Q41359668 | ||
| Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain | Q42479973 | ||
| Ventral tegmental microinjection of delta 9-tetrahydrocannabinol enhances ventral tegmental somatodendritic dopamine levels but not forebrain dopamine levels: evidence for local neural action by marijuana's psychoactive ingredient | Q42502076 | ||
| Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. | Q42553964 | ||
| Inhibition of naloxone-induced withdrawal in morphine dependent mice by 1-trans-delta9-tetrahydrocannabinol | Q43308610 | ||
| Morphine-dependent rats: blockade of precipitated abstinence by tetrahydrocannabinol | Q43309203 | ||
| delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors | Q44345904 | ||
| Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism | Q44346123 | ||
| Effects of body weight levels on Cannabis self-injection | Q47289171 | ||
| Facilitation of brain stimulation reward by delta 9-tetrahydrocannabinol | Q48163060 | ||
| Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase | Q48251232 | ||
| Cannabinoid transmission and reward-related events | Q48285165 | ||
| Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids | Q48383234 | ||
| Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors | Q48518726 | ||
| Delta 9-tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex | Q48859883 | ||
| 1-Δ 9 -Tetrahydrocannabinol: Neurochemical and Behavioral Effects in the Mouse | Q49047868 | ||
| Cannabinoid inhibition of adenylate cyclase: relative activity of constituents and metabolites of marihuana. | Q51199634 | ||
| Drug preference and mood in humans: diazepam. | Q51272041 | ||
| Reliability, validity, and clinical application of the Visual Analogue Mood Scale. | Q51309665 | ||
| Conditioned place preference induced by delta 9-tetrahydrocannabinol: comparison with cocaine, morphine, and food reward. | Q51615260 | ||
| Genetic differences in delta 9-tetrahydrocannabinol-induced facilitation of brain stimulation reward as measured by a rate-frequency curve-shift electrical brain stimulation paradigm in three different rat strains. | Q52203929 | ||
| Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man. | Q53752479 | ||
| Analgesic properties of the tetrahydrocannabinols, their metabolites, and analogs | Q66960058 | ||
| The effects of morphine and ?-9-tetrahydrocannabinol on motor activity in rats | Q67260725 | ||
| Tolerance to the effect of delta9-tetrahydrocannabinol in mice on intestinal motility, temperature and locomotor activity | Q67263227 | ||
| Comparative analgesic activity of various naturally occurring cannabinoids in mice and rats | Q67295067 | ||
| Naltrexone: disposition, metabolism, and effects after acute and chronic dosing | Q67785436 | ||
| Failure to obtain "cannabis-directed behavior" and abstinence syndrome in rats chronically treated with cannabis sativa extracts | Q68776709 | ||
| Evaluation of reinforcing capability of delta-9-tetrahydrocannabinol in rhesus monkeys | Q68790350 | ||
| Delta 9-tetrahydrocannabinol facilitates striatal dopaminergic transmission | Q69359129 | ||
| Studies of EN-1639A (Naltrexone): A New Narcotic Antagonist | Q69762963 | ||
| The effects of delta 9-tetrahydrocannabinol on potassium-evoked release of dopamine in the rat caudate nucleus: an in vivo electrochemical and in vivo microdialysis study | Q69853528 | ||
| Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man | Q71783769 | ||
| Antagonism by chlornaltrexamine of some effects of delta 9-tetrahydrocannabinol in rats | Q72902340 | ||
| P433 | issue | 3 | |
| P921 | main subject | tetrahydrocannabinol | Q190067 |
| naltrexone | Q409587 | ||
| cannabinoids | Q422936 | ||
| P304 | page(s) | 251-260 | |
| P577 | publication date | 2000-06-01 | |
| P1433 | published in | Drug and Alcohol Dependence | Q5308875 |
| P1476 | title | Naltrexone does not block the subjective effects of oral Delta(9)-tetrahydrocannabinol in humans. | |
| P478 | volume | 59 |
| Q57297866 | Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder |
| Q37317906 | Actions of delta-9-tetrahydrocannabinol in cannabis: relation to use, abuse, dependence |
| Q38916400 | Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users? |
| Q37156258 | Biomarkers for the effects of cannabis and THC in healthy volunteers |
| Q30807024 | Cannabinoids: reward, dependence, and underlying neurochemical mechanisms--a review of recent preclinical data |
| Q36655914 | Effects of daily delta-9-tetrahydrocannabinol treatment on heroin self-administration in rhesus monkeys |
| Q36876852 | Effects of delta-9-tetrahydrocannabinol on evaluation of emotional images |
| Q34489831 | Endogenous opiates: 2000. |
| Q36344310 | Interactions between Delta(9)-tetrahydrocannabinol and mu opioid receptor agonists in rhesus monkeys: discrimination and antinociception |
| Q37564992 | Interactions between Δ(9)-tetrahydrocannabinol and heroin: self-administration in rhesus monkeys |
| Q36059911 | Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers. |
| Q50594258 | Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans. |
| Q37660087 | New therapeutic potential for psychoactive natural products |
| Q50107527 | Open-label pilot study of injectable naltrexone for cannabis dependence |
| Q34072888 | Opioid antagonism enhances marijuana's effects in heavy marijuana smokers |
| Q44332720 | Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers |
| Q36948826 | Pharmacological and psychosocial interventions for cannabis use disorders |
| Q35210350 | Pharmacological treatment of cannabis dependence |
| Q24648976 | Pharmacotherapy for cannabis dependence: how close are we? |
| Q26746192 | Progress toward pharmacotherapies for cannabis-use disorder: an evidence-based review |
| Q34575176 | Psychoactive drugs and false memory: comparison of dextroamphetamine and δ-9-tetrahydrocannabinol on false recognition |
| Q46437601 | Reinforcing effects of oral Delta9-THC in male marijuana smokers in a laboratory choice procedure |
| Q36149174 | Self-administration of cannabinoids by experimental animals and human marijuana smokers |
| Q24607810 | State of the art treatments for cannabis dependence |
| Q34319831 | The drug effects questionnaire: psychometric support across three drug types |
| Q44343876 | The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys |
| Q46438870 | Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans |
Search more.